Johnson & Johnson acquires its 1st Chinese medical device maker; Aethlon expects $1.4M in full-year revenues; Washington group pushes women's pelvic health; Invest in R&D, survey says; plus, GPO deals, a Funding Roundup and analysts' ups and downs.

Health care giant Johnson & Johnson (NYSE:JNJ) made its 1st acquisition in China this week, picking up Guangzhou Bioseal Biotech for an undisclosed amount.
J&J has been doing business in China for more than 25 years, including last year's launch of a medical device and diagnostics innovation center there.
Covidien’s 3-year study results showing positive outcomes for its Urgent PC Neuromodulation system in...
NEC Display Solutions wins 510(k) clearance for its 21-inch medical monitor systems.
J&J's former head of global cardiology makes the jump to CEO at Itamar Medical
Sunshine Heart raises $1.5 million of a hoped-for $25.5 million equity funding round.
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with...